Exceptional Occurrence of Amyotrophic Lateral Sclerosis Under Anti-PD-1

Robert M1, Gohard F1, Ruellan AL2, Espitalier F3, Le Naour S1 and Quéreux G1,4*

1Department of Dermatology, University Hospital of Nantes, France
2Centre Régional de Pharmacovigilance de Nantes, CHU Nantes, France
3ORL, CHU Nantes, France
4CIC 1413, Inserm UMR 1302/EMR6001 INCIT, France

^*Correspondance to: Gaëlle Quéreux 

 PDF  Full Text Case Report | Open Access

Abstract:

We report the exceptional observation of a patient treated with Nivolumab for a melanoma who developed amyotrophic lateral sclerosis. In the literature, ALS has only been reported once as an adverse effect of ICIs. Over the past decade, cancer immunotherapy with Immune Checkpoint Inhibitors (ICIs) has significantly improved the outcome of many malignancies. However, with the broad use of ICIs, neurological immune related Adverse Events (irAE) are increasingly recognized. Myositis are the most frequent neurological complication, followed by peripheral neuropathies, myasthenic syndrome, encephalitis, cranial neuropathy, central nervous system demyelinating disease/ myelopathy, and aseptic meningitis. Despite the few cases described, it is important to think of ALS when phonation and swallowing disorders appear under immunotherapy.

Keywords:

Immunotherapy; Immune checkpoint inhibitor; Amyotrophic lateral sclerosis; Melanoma

Cite the Article:

Robert M, Gohard F, Ruellan AL, Espitalier F, Le Naour S, Quéreux G. Exceptional Occurrence of Amyotrophic Lateral Sclerosis Under Anti-PD-1. Ann Clin Case Rep. 2024; 9: 2634..